Wolverine Stack 5mg/5mg
EXPRESS Apple Pay afterpay
BPC-157 + TB-500 at a glance
Inside the 10mg blend
This research formulation contains two named peptide components in equal nominal masses. The 10mg label describes their combined quantity rather than 10mg of each individual peptide.
BPC-157
50% of stated formulation ยท Synthetic 15-amino-acid peptide investigated in experimental tissue and cellular models.
TB-500
50% of stated formulation ยท Thymosin beta-4-associated research peptide whose exact molecular form should be established analytically.
The 5mg + 5mg composition is a label claim. It does not independently establish the measured content of the two compounds in a specific batch.
Two distinct peptide research pathways
BPC-157 and TB-500 are different research materials. Their scientific backgrounds should be considered individually before evaluating a fixed-ratio formulation containing both.
Tendon-cell behaviour
BPC-157 has been investigated in laboratory tendon explants and fibroblast cultures, with measurements involving cell movement, survival and tissue outgrowth.
Cell migration biology
Related full-length thymosin beta-4 literature investigates actin-related cellular functions and cell movement. These findings cannot automatically be assigned to the shorter TB-500 fragment.
Extracellular matrix
Experimental studies examine cell attachment, migration and matrix-related processes involved in how cells interact with their surrounding structures.
These are individual research pathways. They do not establish that the combined product has additive or synergistic biological effects.
What has the research investigated?
Published research provides experimental context for BPC-157 and thymosin beta-4-related compounds. These findings do not establish clinical outcomes for a premixed BPC-157 + TB-500 formulation.
Chang et al. ยท Journal of Applied Physiology (2011)
A laboratory investigation examined BPC-157 in tendon explants and tendon fibroblast cultures. Researchers measured tendon-cell outgrowth, migration, survival under oxidative stress and related cellular signalling. These findings concern BPC-157 in the specific experimental systems, not the premixed blend.
Malinda et al. ยท Journal of Investigative Dermatology (1999)
Experimental research with full-length thymosin beta-4 examined re-epithelialisation, collagen deposition, angiogenesis and cell migration in wound-related models. The material was full-length thymosin beta-4, not necessarily the TB-500 fragment listed in this blend.
BPC-157 ยท Preclinical evidence reviews
Reviews of BPC-157 research describe a literature base dominated by preclinical studies, including tendon, muscle, ligament and gastrointestinal models. Controlled human evidence remains limited.
TB-500 ยท Molecular identity research
TB-500 has been identified as an acetylated seven-amino-acid fragment associated with thymosin beta-4. Since the TB-500 name is used inconsistently in some commercial contexts, exact structural identification is important when comparing research publications with a supplied sample.
No controlled human trial establishing efficacy for the complete 5mg BPC-157 + 5mg TB-500 formulation is identified in the cited research.
BPC-157 + TB-500 blend vs separate vials
A premixed blend contains the two nominal ingredients together in a constant ratio. Separate research materials allow each component to be investigated and characterised independently.
| Characteristic | Premixed blend | Separate vials |
|---|---|---|
| Components | Both in one vial | One per vial |
| Stated mass ratio | Fixed at 1:1 | Independently specified |
| Can one component vary alone? | No | Yes |
| Laboratory design | Fixed-composition samples | Component-specific controls |
| Combined clinical effect established? | No | No |
Combining two compounds in one vial does not establish improved results, equivalent molecular behaviour or a clinically validated interaction.
Melbourne stock. Nationwide dispatch.
Halo Bio holds stock in Melbourne and offers same-day dispatch for eligible in-stock orders placed before 2pm on business days, subject to payment confirmation. Tracking information is supplied during fulfilment, with delivery times dependent on destination and carrier.
BPC-157 + TB-500 research FAQs
What is BPC-157 + TB-500?
It is a fixed-ratio laboratory research formulation containing two named peptide components, BPC-157 and TB-500.
What is in the 10mg blend?
The nominal composition is 5mg BPC-157 and 5mg TB-500, giving 10mg total labelled material in a 1:1 mass ratio.
Does 10mg mean 10mg of each peptide?
No. It means 10mg combined, consisting of 5mg of each named component.
What is the Wolverine Stack?
Wolverine Stack is a common commercial nickname for a BPC-157 and TB-500 combination. It is not the scientific name of a single new peptide.
What is BPC-157 studied for?
BPC-157 has been investigated predominantly in laboratory and preclinical tissue research, including tendon-cell behaviour, cell migration and gastrointestinal models.
What is TB-500 studied for?
TB-500 is associated with thymosin beta-4 fragment research. Related scientific literature examines actin biology, cell migration and wound-related pathways, although many studies used full-length thymosin beta-4 rather than TB-500.
Is TB-500 the same as thymosin beta-4?
Not necessarily. The analytically identified TB-500 fragment is commonly described as acetylated LKKTETQ, containing seven amino acids. Full-length thymosin beta-4 contains 43 amino acids.
Has the complete combination been clinically studied?
The cited publications do not establish controlled human clinical evidence for this fixed BPC-157 5mg plus TB-500 5mg formulation.
Is a premixed blend different from separate vials?
Yes. A premixed vial has a constant stated component ratio, whereas separate vials allow the materials to be investigated independently.
Does combining BPC-157 and TB-500 establish stronger effects?
No. A combined effect or interaction requires direct experimental evidence using the actual mixture and appropriate controls.
What does the 10mg label claim mean?
It represents the combined nominal quantities. The label does not by itself verify batch identity, purity or actual content.
Is the product suitable for human or animal use?
No. Halo Bio supplies this formulation for laboratory research only, not for human or animal consumption, injection, self-administration or clinical treatment.
When will my order be dispatched?
Eligible in-stock orders placed before 2pm on business days are dispatched from Melbourne the same day, following payment confirmation.
Independent scientific publications
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival and cell migration. Journal of Applied Physiology, 2011.
Read publication โ - Malinda KM et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology, 1999.
Read publication โ - Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 2012.
- Ho ENM et al. Doping control analysis of TB-500 in equine urine and plasma. Drug Testing and Analysis, 2012.
- US Food and Drug Administration. TB-500-related bulk drug substances: scientific assessment, 2026.
View FDA scientific background โ
These sources concern individual materials or associated molecular research. They do not constitute clinical trials or batch-specific verification of the combined Halo Bio formulation.
Laboratory research use only.
Not intended for human or animal consumption, injection, self-administration, diagnostic use or clinical treatment. Published experimental findings do not establish the identity, purity, sterility, safety or performance of this separately supplied two-component research blend. Refer to batch-specific analytical documentation and verified laboratory handling instructions where available.